Eli Lilly (NYSE: LLY) announced a global research collaboration with Seamless Therapeutics to develop programmable gene ...

Intellia Therapeutics stock surged Tuesday after the FDA aid it would allow the company to restart a gene-editing study.

The global cell therapy market was valued at $5.88 billion in 2024 and is on track to hit $44.39 billion by 2034, expanding at a striking 22.69% CAGR. Researchers credit this explosive growth to ...

DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...

In this article, we will take a look at the 9 Best Gene-Editing Stocks to Buy According to Hedge Funds. Genetic manipulation – or gene editing – is a concept that describes altering the genetic ...

The stock has lost significant market value since that debacle. While it's not clear that nex-z was responsible, it's also ...

And, if all goes well, over the next five years as well.

Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 2, 2026 /PRNewswire/ -- Equity Insider News Commentary – The gene therapy market is surging toward $36.55 billion by 2032, powered by ...

Beam Therapeutics is one of the few biotechs that has shown immense potential in the gene therapy space. The company’s proprietary base-editing technology potentially enables the development of a ...

Krystal Biotech, Inc. (NASDAQ:KRYS) is one of the best gene-editing stocks to buy according to hedge funds. On November 5, Evercore ISI’s Gavin Clark-Gartner affirmed a Buy rating on Krystal Biotech, ...

The MarketWatch News Department was not involved in the creation of this content. Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 2, 2026 /CNW/ -- Equity Insider News Commentary -- The ...